US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
ALX Oncology Holdings Inc (ALXO)
ALX Oncology Holdings Inc (ALXO) ニュース

ALX Oncology Holdings Inc (ALXO)

2.04

0.245

(13.65%)

終値： 6月27日 5:00AM

2.0287

-0.0113

( -0.55% )

取引時間後: 7:27AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Form 8-K - Current report

Form 8-K - Current report

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all...

ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven...

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,”...

Form 8-K - Current report

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical...

TrendTrade2016

TrendTrade2016 4月前

ALXO..THE BIO BEAST IS READY TO BEAST THROUGH BIO BEASTSVILLE

TrendTrade2016

TrendTrade2016 5月前

ALXO..THE HOTTEST CANCER PLAY OUT THERE

TrendTrade2016

TrendTrade2016 5月前

ALXO THE NEXT BIO BEAST READY TO BEAST THROUGH BEASTVILLE

TrendTrade2016

TrendTrade2016 5月前

https://www.sec.gov/Archives/edgar/data/1810182/0001278411-26-000002-index.html

TrendTrade2016

TrendTrade2016 5月前

ALXO bio beast gapping hard

TrendTrade2016

TrendTrade2016 5月前

ALXO BACK IN PLAY

glenn1919

glenn1919 5月前

ALXO.........................................................https://stockcharts.com/sc3/ui/?s=ALXO&p=W&b=5&g=0&id=p86431144783

INV4

Jefferies initiates coverage on ALX Oncology stock with Buy rating

Nov 13, 2025

Investing.com - Jefferies initiated coverage on ALX Oncology (NASDAQ:ALXO) with a Buy rating and a $4.00 price target on Thursday, suggesting significant upside potential from the current price of $1.28. This bullish outlook aligns with the broader analyst consensus of 1.75 (Buy) for the micro-cap biotech, which currently has a market capitalization of just $68.55 million.

https://ng.investing.com/news/analyst-ratings/jefferies-initiates-coverage-on-alx-oncology-stock-with-buy-rating-93CH-2206352

$ALXO

glenn1919

glenn1919 7月前

ALXO.......................................https://stockcharts.com/sc3/ui/?s=ALXO&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 9月前

ALXO........................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 9月前

ALXO.....................................................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

TrendTrade2016

TrendTrade2016 9月前

ALXO ready for 2.00

TrendTrade2016

TrendTrade2016 9月前

TrendTrade2016

TrendTrade2016 9月前

ALXO first target break and now 1.60 is next

TrendTrade2016

TrendTrade2016 9月前

ALXO target approach

glenn1919

glenn1919 9月前

ALXO..................................................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 9月前

ALXO......................................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 10月前

ALXO.....................................................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

TrendTrade2016

TrendTrade2016 10月前

ALXO GAPPING AS WE HEAD TO TARGET

TrendTrade2016

TrendTrade2016 10月前

ALXO GETTING TRACTION

glenn1919

glenn1919 10月前

ALXO...................................................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

TrendTrade2016

TrendTrade2016 10月前

ALXO SLOW AND STEADY TO 1.52

TrendTrade2016

TrendTrade2016 10月前

ALXO NO DILUTION

TrendTrade2016

TrendTrade2016 10月前

ALXO HERE WE GO

TrendTrade2016

TrendTrade2016 10月前

ALXO READY TO BREAK 1.00

INV4

Form 4 - Statement of changes in beneficial ownership of securities

August 20, 2025

https://investorshub.advfn.com/stock-market/NASDAQ/alx-oncology-ALXO/stock-news/96676921/form-4-statement-of-changes-in-beneficial-owners

$ALXO

TrendTrade2016

TrendTrade2016 10月前

ALXO BIO BEAST INTO CLOSE

INV4

glenn1919

glenn1919 1年前

ALXO............................................................................................p/m

glenn1919

glenn1919 1年前

ALXO.................................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 1年前

alxo......................https://stockcharts.com/h-sc/ui?s=alxo&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 2年前

ALXO...........................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 2年前

ALXO..............................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 2年前

ALXO new 52 week low

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

ALXO new 52 week low

tbonaces80

tbonaces80 2年前

tbonaces80

tbonaces80 2年前

Loaded and halted 20%short. Hahahah

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

ALXO new 52 week high

Monksdream

Monksdream 2年前

ALXO new 52 week high

Monksdream

Monksdream 3年前

ALXO new 52 week high

MiamiGent

MiamiGent 3年前

ALXO $15.23 +2.20 (+16.88%)

Well, there's the few % I was thinking of but why get off here? There's no sign of the drift up stopping...

https://stockcharts.com/h-sc/ui?s=ALXO

https://finance.yahoo.com/news/alx-oncology-holdings-inc-alxo-214706863.html

Jefferies Upgrades ALX Oncology Holdings to Buy, Raises Price Target to $18
BENZINGA 6:27 AM ET Dec-08-2023
Jefferies analyst Michael Yee upgrades ALX Oncology Holdings (ALXO.NaE) from Hold to Buy and raises the price target from $8 to $18.

Form SC 13D/A ALX ONCOLOGY HOLDINGS Filed by: LSV Associates, LLC
10K WIZARD
6:00 AM ET Dec-20-2023
http://archive.fast-edgar.com/20231220/AHBYD22D8M2232ZZ272F2WZZHEUJZ2Z2Z252
Filed on: December 20, 2023

Refinitiv/Verus upgrades ALX ONCOLOGY HOLDINGS ORD SHS from SELL to HOLD.
INVESTARS ANALYST ACTIONS - PUBLIC - 1:13 PM ET Nov-27-2023
On November 27, 2023 Refinitiv/Verus upgraded ALX ONCOLOGY HOLDINGS ORD SHS from SELL to HOLD.

MiamiGent

MiamiGent 3年前

ALXO In at $14.86 +1.83 (+14.04%)
As of Dec-22-202311:12:41 AM ET

https://stockcharts.com/h-sc/ui?s=ALXO

See if I might catch a few % of this drift up.

Good Phase 2 Interim Results
Upgrade
Short squeeze
Significant add by stakeholder

Monksdream

Monksdream 3年前

ALXO new 52 week high
Compare to Marathon Digital

make it happen

make it happen 3年前

This is a weird one has more cash than market cap after closing this and Cantor Fitzgerald moves price target up to $23.0 and UBS to $27.00

make it happen

make it happen 3年前

Agreed and volume is not sustainable. Daily showing $5.04 thinking closes gap @ $6.00

stock1ace1

stock1ace1 3年前

Pt3

Any offering yet

Apple iSport (QB)

UBS MSCI EMU Socially Re...

Bluestone Resources

Almonty Industries

Incomeshares Alphabet Go...

Estrella Immunopharma

Euronext Multi Sector Eu...

Jindalee Lithium

Parker Hannifin

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。